Guest guest Posted August 28, 2008 Report Share Posted August 28, 2008 Virginia,A few weeks ago you discussed the practice of " wetting " hormones as a first step in the process of compounding them into bases. This information was a real eye-opener for me: i had be operating under the illusion that when i ordered my emu oil-based hormones all i was getting was the oil and hormone and nothing else. I was not a happy camper when, contacting my compounding pharmacy to ask, i learned that they used either propylene glycol or glycerin as their wetting agent. They were more than willing to make sure that any future rx's use only glycerine, but the fact that all this time i've possibly been exposed to pg, something i've gone out of my way to avoid, doesn't thrill me.My questions: i think you mentioned that some, but not all, pharmacies skip using a wetting agent at all. Is that true? Are wetting agents used because, being powders, the hormones are more difficult to work with without them? And, if you're willing, i'd be extremely interested in knowing just how the wetting process works. Based on what you tell me, i'm considering asking my pharmacy (Bellevue in St. Louis) if they'd be willing to forego using a wetting agent at all, since even the use of glycerin, a possible yeast-producer, doesn't thrill me either (though it sure bets pg!)Thanks so much for any further information you can give me.Hollis > > > > http://cebp. aacrjournals. org/cgi/content/ abstract/ 17/8/2029> > > > Circulating 2-Hydroxy- and 16-Hydroxy Estrone Levels and Risk of > > Breast Cancer among Postmenopausal Women > > A. Eliassen1,3, Stacey A. Missmer1,2,3, S. > > Tworoger1,3 and E. Hankinson1,3 > > 1 Channing Laboratory, Department of Medicine, and 2 Department of > > Obstetrics, Gynecology, and Reproductive Biology, Brigham and > Women's > > Hospital and Harvard Medical School and 3 Department of > Epidemiology, > > Harvard School of Public Health, Boston, Massachusetts > > > > Circulating estrogens are associated with breast cancer risk in > > postmenopausal women. Given that estrogen metabolites are > potentially > > both mitogenic and genotoxic, it is possible that plasma levels of > > estrogen metabolites are related to breast cancer risk. We > conducted > > a prospective, nested case-control study within the Nurses' Health > > Study. Blood samples, collected in 1989 to 1990, were assayed for > 2- > > OH and 16-OH estrone among 340 cases and 677 matched controls not > > taking postmenopausal hormones. Multivariate relative risks (RR) > and > > 95% confidence intervals (95% CI) were calculated by conditional > > logistic regression, adjusting for breast cancer risk factors. > > Neither 2-OH nor 16-OH estrone concentrations were significantly > > associated with breast cancer risk overall (top versus bottom > > quartile: RR, 1.19; 95% CI, 0.80-1.79; Ptrend = 0.40 for 2-OH > estrone > > and RR, 1.04; 95% CI, 0.71-1.53; Ptrend = 0.81 for 16-OH estrone). > > The ratio between the two metabolites (2-OH:16-OH estrone) was > > similarly unrelated to risk overall (1.30; 95% CI, 0.87-1.95; > Ptrend > > = 0.35). Although no associations were detected among women with > > estrogen receptor (ER)–positive/ progesterone receptor (PR)– > positive > > tumors, significant positive associations were observed for 2-OH > > estrone and the 2-OH:16-OH estrone ratio among women with ER- > > negative/PR- negative tumors (RR, 3.65; 95% CI, 1.23-10.81; Ptrend > = > > 0.01; Pheterogeneity = 0.02 for 2-OH estrone; RR, 3.70; 95% CI, > 1.24- > > 11.09; Ptrend = 0.004; Pheterogeneity = 0.005 for 2-OH:16-OH > > estrone). These data do not support the hypothesized inverse > > associations with 2-OH estrone and the 2-OH:16-OH estrone ratio or > > the hypothesized positive association with 16-OH estrone. The > > significant positive associations with 2-OH estrone and the 2- > OH:16- > > OH estrone ratio among women with ER-negative/ PR-negative tumors > > needs to be replicated in future studies. (Cancer Epidemiol > > Biomarkers Prev 2008;17(8):2029– 35) > > > > Virginia (who broke her right upper arm on Tuesday...4- 6 weeks in > a > > sling, then physical therapy) > > > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted August 28, 2008 Report Share Posted August 28, 2008 I spoke recently about the wetting process to the compounding pharmacist here, and he said that the wetting was necessary for getting the substances to mix; if you don't use some kind of wetting agent, the powders (the dry ingredients in the compound) won't fully integrate into the cream. I called PCCA, and for one gram of powder (the hormone), the pharmacist should use one ml of glycerin (there is natural glycerin and synthetic; of course, you want the natural). Virginia > >> > >> http://cebp. aacrjournals. org/cgi/content/ abstract/ 17/8/2029 > >> <http://cebp.aacrjournals.org/cgi/content/abstract/17/8/2029> > >> Circulating 2-Hydroxy- and 16-Hydroxy Estrone Levels and Risk of > >> Breast Cancer among Postmenopausal Women A. Eliassen1,3, > >> Stacey A. Missmer1,2,3, S. Tworoger1,3 and E. > >> Hankinson1,3 1 Channing Laboratory, Department of Medicine, and 2 > >> Department > of > >> Obstetrics, Gynecology, and Reproductive Biology, Brigham and > > Women's > >> Hospital and Harvard Medical School and 3 Department of > > Epidemiology, > >> Harvard School of Public Health, Boston, Massachusetts > >> Circulating estrogens are associated with breast cancer risk in > >> postmenopausal women. Given that estrogen metabolites are > > potentially > >> both mitogenic and genotoxic, it is possible that plasma levels > of > >> estrogen metabolites are related to breast cancer risk. We > > conducted > >> a prospective, nested case-control study within the Nurses' > Health > >> Study. Blood samples, collected in 1989 to 1990, were assayed for > > 2- > >> OH and 16-OH estrone among 340 cases and 677 matched controls not > >> taking postmenopausal hormones. Multivariate relative risks (RR) > > and > >> 95% confidence intervals (95% CI) were calculated by conditional > >> logistic regression, adjusting for breast cancer risk factors. > >> Neither 2-OH nor 16-OH estrone concentrations were significantly > >> associated with breast cancer risk overall (top versus bottom > >> quartile: RR, 1.19; 95% CI, 0.80-1.79; Ptrend = 0.40 for 2-OH > > estrone > >> and RR, 1.04; 95% CI, 0.71-1.53; Ptrend = 0.81 for 16-OH > estrone). > >> The ratio between the two metabolites (2-OH:16-OH estrone) was > >> similarly unrelated to risk overall (1.30; 95% CI, 0.87-1.95; > > Ptrend > >> = 0.35). Although no associations were detected among women with > >> estrogen receptor (ER)–positive/ progesterone receptor (PR)– > > positive > >> tumors, significant positive associations were observed for 2-OH > >> estrone and the 2-OH:16-OH estrone ratio among women with ER- > >> negative/PR- negative tumors (RR, 3.65; 95% CI, 1.23-10.81; Ptrend > > = > >> 0.01; Pheterogeneity = 0.02 for 2-OH estrone; RR, 3.70; 95% CI, > > 1.24- > >> 11.09; Ptrend = 0.004; Pheterogeneity = 0.005 for 2-OH:16-OH > >> estrone). These data do not support the hypothesized inverse > >> associations with 2-OH estrone and the 2-OH:16-OH estrone ratio > or > >> the hypothesized positive association with 16-OH estrone. The > >> significant positive associations with 2-OH estrone and the 2- > > OH:16- > >> OH estrone ratio among women with ER-negative/ PR-negative tumors > >> needs to be replicated in future studies. (Cancer Epidemiol > >> Biomarkers Prev 2008;17(8):2029– 35) > >> Virginia (who broke her right upper arm on Tuesday...4- 6 weeks in > > a > >> sling, then physical therapy) > > > > <http://cebp.aacrjournals.org/cgi/content/abstract/17/8/2029> > Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.